Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
June 9, 2008

Cobrabio to Manufacture ViroMed Oncology Vaccine

  • Cobra Biomanufacturing will produce ViroMed’s VM206RY, a plasmid DNA treatment for tumors expressing Her2/neu. Cobrabio will manufacture ViroMed’s master cell bank and GMP-grade VM206RY for the first clinical trials, which will be held in Korea and in the U.S.

    VM206 is an anticancer vaccine targeting Her2/neu-positive breast or ovarian cancer. The compound has shown in preclinical studies to elicit an immune response to Her-2, resulting in the reduction in the growth and the recurrence rate of breast or ovarian cancer.

  • You’re all set! Thank you for subscribing to GEN Highlights.